Related Experiment Videos
C-reactive protein in patients with familial hypercholesterolemia: no effect of simvastatin therapy
M F Mohrschladt1, M P de Maat, R G Westendorp
1Department of General Internal Medicine, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands.
Insights
C-reactive protein (CRP) is linked to cardiovascular disease (CVD) in familial hypercholesterolemia (FH) patients. One year of simvastatin treatment did not significantly alter CRP levels in this high-risk group.
Area of Science:
- Biochemistry
- Cardiology
- Pharmacology
Background:
- Familial hypercholesterolemia (FH) patients face elevated risks of premature cardiovascular disease (CVD).
- C-reactive protein (CRP) is a key predictor of future CVD events, indicating its role in atherosclerosis.
- Understanding CRP dynamics in FH is crucial for managing cardiovascular risk.
Purpose of the Study:
- To assess the impact of one-year simvastatin treatment on serum CRP levels in FH patients.
- To investigate the association between CVD risk factors and CRP concentrations in FH.
- To determine if simvastatin therapy influences CRP levels in FH patients.
Main Methods:
- Baseline CRP levels measured in 337 FH patients.
- Subgroup analysis of 129 patients after one year of simvastatin (20-40 mg/day) treatment.
- Correlation analysis of CRP with CVD risk factors including smoking, BMI, age, triglycerides, and medication use.
Main Results:
- FH patients with existing CVD had significantly higher baseline CRP levels (2.26 mg/l vs. 1.55 mg/l).
- CRP levels correlated with smoking, body mass index, age, triglyceride levels, and use of NSAIDs or anticoagulants.
- Simvastatin improved lipid profiles but did not significantly decrease CRP levels (median decrease from 1.51 to 1.24 mg/l, P=0.328).
Conclusions:
- Elevated CRP levels are associated with the presence of CVD in familial hypercholesterolemia patients.
- Simvastatin therapy, while improving lipid profiles, demonstrated no significant effect on CRP levels in this cohort.
- Further research may explore other interventions targeting CRP in FH for CVD risk reduction.
Abstract:
Patients with familial hypercholesterolemia (FH) are especially at risk for premature cardiovascular disease (CVD). Recent studies revealed C-reactive protein (CRP) as a strong predictor of future first or recurrent CVD events, suggesting that CRP plays an important role in the development of atherosclerosis. The aim of this study was to evaluate the effect of one year of simvastatin treatment on serum levels of CRP and to assess the influence of risk factors for CVD on CRP concentrations in patients with FH. We measured baseline CRP levels in 337 patients with FH. A second blood sample, collected after one year of treatment with simvastatin (20--40 mg once daily) was measured in a subgroup of 129 patients. Patients with CVD present at baseline had significantly higher serum levels of CRP (2.26 mg/l versus 1.55 mg/l, P<0.001). CRP levels were associated with smoking, body mass index, age, levels of triglycerides (TG), and the use of NSAIDs or anticoagulation drugs. Simvastatin therapy significantly improved lipid profiles in the intervention group. There was a small, but non-significant decrease of CRP levels upon treatment. CRP decreased from 1.51 mg/l median (interquartile range (IQR) 0.76--3.41) at baseline to 1.24 mg/l median (IQR 0.72--2.92) after treatment, (P=0.328). In conclusion, CRP levels were associated with the presence of CVD in FH patients. Simvastatin therapy had no significant effect on CRP levels in these patients.